Organon adds Eli Lilly migraine meds to women’s health portfolio in Europenews2023-12-18T19:33:56+00:00December 18th, 2023|Endpoints News|
Arcutis scores FDA approval for new foam treatment for common skin conditionnews2023-12-18T19:17:39+00:00December 18th, 2023|Endpoints News|
Atara Biotherapeutics to lay off 73 California employees by the end of the yearnews2023-12-18T19:07:28+00:00December 18th, 2023|Endpoints News|
FDA finalizes opioid safety labeling changesnews2023-12-18T18:11:57+00:00December 18th, 2023|Endpoints News|
Invivyd’s stock soars after positive early PhIII monoclonal antibody data revealnews2023-12-18T16:31:07+00:00December 18th, 2023|Endpoints News|
Point Biopharma’s prostate cancer radioligand study disappoints as Lilly again extends offernews2023-12-18T16:17:13+00:00December 18th, 2023|Endpoints News|
First Wave to merge with ImmunogenX; Caliway raises $100M; New deals for Replay’s Syenanews2023-12-18T16:03:02+00:00December 18th, 2023|Endpoints News|
Novo Nordisk Foundation to launch $260M vaccine initiative in early 2024news2023-12-18T13:28:50+00:00December 18th, 2023|Endpoints News|
Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes datanews2023-12-18T12:30:09+00:00December 18th, 2023|Endpoints News|
FDA rejects Checkpoint Therapeutics’ PD-L1 drug cosibelimab over manufacturing issuesnews2023-12-18T12:28:54+00:00December 18th, 2023|Endpoints News|
